Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Interferon-γ signaling contributes to drug resistance in AML

Hussein Abbas • 9 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia Venetoclax

Hussein Abbas, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of inflammatory mediators on therapy responses and outcomes in acute myeloid leukemia (AML). Specifically, he highlights the role of interferon-γ in influencing T-cell activity and contributing to drug resistance, including resistance to venetoclax. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hussein Abbas

0:37
The mechanism of treatment resistance in AML: do CD8-expressing T-cells become exhausted?
Hussein Abbas • 9 Dec 2023
0:38
The functional role of CD4- and CD8-expressing T-cells in AML
Hussein Abbas • 9 Dec 2023
0:44
Predictors of poor response to azacitidine, venetoclax, and magrolimab in TP53-mutated AML
Hussein Abbas • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals